Clicky

Krystal Biotech, Inc.(KRYS) News

Date Title
Jul 24 Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
Jul 24 Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position
Jul 10 KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Jul 9 Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Jul 7 Exploring High Growth Tech Stocks In The US Market
Jul 7 High Insider Ownership In 3 Promising Growth Companies
Jul 2 Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Jun 27 3 Promising Genomics Stocks to Keep an Eye On in 2025
Jun 25 KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
Jun 25 Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Jun 24 Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Apr 17 Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
Apr 8 Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Apr 7 Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer
Apr 7 5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Feb 24 Why Krystal Biotech (KRYS) Might be Well Poised for a Surge
Feb 24 Why Krystal Biotech, Inc. (KRYS) is a Top Momentum Stock for the Long-Term
Feb 21 Krystal Biotech (KRYS) Upgraded to Buy: Here's What You Should Know
Feb 20 Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
Feb 20 3 US Growth Companies With High Insider Ownership Expecting Up To 68% Earnings Growth